Gastrointestinal OTC Drugs Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 41.51 Billion
CAGR (2026-2031)	6.59%
Fastest Growing Segment	Proton Pump Inhibitors
Largest Market	North America
Market Size (2031)	USD 60.88 Billion

Market Overview

The Global Gastrointestinal OTC Drugs Market will grow from USD 41.51 Billion in 2025 to USD 60.88 Billion by 2031 at a 6.59% CAGR. Gastrointestinal over-the-counter (OTC) drugs encompass non-prescription pharmaceutical formulations designed to alleviate digestive ailments, such as gastroesophageal reflux disease, constipation, and diarrhea, without physician intervention. The market is primarily propelled by the rising prevalence of lifestyle-induced digestive disorders and an aging global population that necessitates frequent management of chronic gastrointestinal conditions. Furthermore, healthcare systems worldwide are actively encouraging self-medication to mitigate operational costs and reduce the burden on primary care facilities. The scale of this demand is substantial; according to the Association of the European Self-Care Industry, in 2024, 4.7 billion packs of non-prescription medicines were sold in Europe to manage minor health issues, including gastrointestinal disorders.

Despite these favorable growth drivers, the market faces a significant impediment in the form of stringent regulatory frameworks governing product safety and labeling. Regulatory bodies enforce rigorous standards to prevent adverse effects and ensure consumer protection, which can delay the approval of novel formulations and increase compliance costs for manufacturers. This extensive scrutiny constitutes a major challenge, creating high barriers to entry and potentially slowing the pace of innovation within the global gastrointestinal OTC sector.

Key Market Drivers

The rising prevalence of common gastrointestinal disorders serves as a primary catalyst for the Global Gastrointestinal OTC Drugs Market. Post-pandemic lifestyle shifts have exacerbated the burden of digestive ailments, necessitating accessible therapeutic solutions for conditions such as indigestion and irritable bowel syndrome (IBS). This growing incidence compels consumers to seek immediate relief through non-prescription channels, bypassing the logistical hurdles of clinical consultations. For instance, according to a study published in Clinical Gastroenterology and Hepatology in July 2025, the prevalence of functional dyspepsia in surveyed adults increased from 8.3% pre-pandemic to 11.9% post-pandemic, underscoring the escalating demand for effective digestive remedies.

Increasing consumer preference for self-medication and preventive care further drives market expansion. As individuals become more proactive about their well-being, the adoption of over-the-counter treatments for minor gastric issues has surged, supported by the widening availability of trusted brands and Rx-to-OTC switches. According to Haleon's 'Annual Report 2024', published in February 2025, the company’s Digestive Health and Other segment generated £2.0 billion in revenue, achieving an organic growth of 5.5% driven by innovation in key products. This trend is mirrored in broader health behaviors; according to the 'STADA Health Report 2025', published in June 2025, 66% of Europeans now attend the majority of their preventive checkups, reflecting a 5 percentage point increase in proactive health engagement that fuels the self-care sector.

Download Free Sample Report

Key Market Challenges

Stringent regulatory frameworks governing product safety and labeling constitute a formidable obstacle to the expansion of the Global Gastrointestinal OTC Drugs Market. These rigorous standards, while essential for consumer protection, impose significant operational burdens on manufacturers by necessitating extensive clinical testing and complex approval procedures for new formulations. The high cost and extended timelines associated with achieving compliance deter investment in novel gastrointestinal therapies, effectively slowing the introduction of innovative relief options for conditions like heartburn and indigestion. Consequently, manufacturers are often forced to divert resources away from research and development toward meeting evolving compliance mandates, which creates a substantial barrier to entry for smaller enterprises and stifles overall market dynamism.

The sheer volume of products subject to this oversight underscores the magnitude of the operational challenge facing the industry. According to the Association of the European Self-Care Industry, in 2024, the sector managed over 4,000 non-prescription medicines based on more than 200 different active pharmaceutical ingredients. This extensive portfolio requires continuous regulatory maintenance, meaning that even minor labeling updates or safety re-evaluations can ripple across thousands of product lines. This regulatory density directly impedes the market's agility, making it difficult for companies to rapidly respond to emerging consumer needs in the gastrointestinal sector.

Key Market Trends

The Proliferation of Probiotic and Prebiotic Gut Health Supplements is reshaping the market as consumers increasingly prioritize microbiome optimization for long-term wellness. This trend transcends basic digestive relief, moving towards advanced formulations that target specific conditions such as functional bowel disorders and immune system support through gut modulation. Manufacturers are responding by launching high-potency, strain-specific products that offer clinical validation, thereby legitimizing the segment beyond general wellness. This commercial shift is evident in the financial performance of specialized firms; according to BioGaia, February 2025, in the 'Year-end report January – December 2024', the company’s Adult Health segment net sales increased by 17% for the full year, underscoring the robust global demand for targeted probiotic interventions.

Concurrently, there is a Rising Consumer Preference for Natural and Herbal Digestive Remedies, driven by a desire for "clean label" alternatives to synthetic pharmaceuticals. Consumers are actively seeking plant-based ingredients known for their gentle efficacy and minimal side effects, leading to a surge in products containing botanicals like ginger, peppermint, and turmeric. This demand is compelling OTC manufacturers to reformulate existing lines or introduce herbal adjacencies to capture the holistic-minded demographic. Validating this shift, according to WholeFoods Magazine, February 2025, in the 'Highlights from CRN's 2024 Consumer Survey', usage of ginger, a well-established digestive aid, increased to 13% among supplement users, reflecting the growing integration of traditional botanical solutions into modern self-care regimens.

Segmental Insights

The Proton Pump Inhibitors segment is recognized as the fastest-growing category within the Global Gastrointestinal OTC Drugs Market, primarily driven by the rising prevalence of acid-related conditions such as gastroesophageal reflux disease. This growth is significantly accelerated by strategic regulatory decisions, specifically the approval of prescription-to-over-the-counter switches by bodies like the FDA. These initiatives have expanded consumer access to potent treatments like esomeprazole and omeprazole without the need for physician intervention. Consequently, the combination of enhanced product accessibility and a growing consumer preference for self-medication actively supports the segment's robust expansion.

Regional Insights

North America maintains the leading position in the Global Gastrointestinal OTC Drugs Market, driven by a widespread prevalence of lifestyle-related digestive conditions and a strong consumer preference for self-care. The region is characterized by extensive product availability across established pharmacy and retail networks. Additionally, supportive initiatives by the U.S. Food and Drug Administration regarding prescription-to-over-the-counter switches have expanded access to various therapeutic options. This regulatory environment, coupled with high health literacy among consumers seeking immediate relief for gastrointestinal ailments, solidifies North America as the primary contributor to market demand.

Recent Developments

In December 2024, BioGaia strengthened its position in the Global Gastrointestinal OTC Drugs Market by launching BioGaia Gastrus PURE ACTION in the United States. This new probiotic supplement was specifically formulated for adults with sensitive stomachs, featuring a clean, double-strength, and FODMAP-friendly composition. The product contains a patented blend of probiotic strains intended to support individuals with occasional gut discomfort and improve overall digestive health. This launch represented the company's continued investment in science-backed solutions to meet the evolving needs of consumers seeking effective and specialized gut health management.
In June 2024, Kenvue broadened its offerings in the Global Gastrointestinal OTC Drugs Market with the launch of Pepcid Icy Cool Mint. This new over-the-counter heartburn medication was developed to provide fast-acting and long-lasting relief accompanied by an instant cooling sensation for consumers. The product was formulated to control acid all day or night with just one tablet, directly addressing the needs of the millions of individuals suffering from heartburn. This addition to the brand's portfolio underscored the company's focus on delivering innovative symptom relief solutions to the competitive digestive health sector.
In April 2024, Bayer Consumer Health expanded its presence in the Global Gastrointestinal OTC Drugs Market by introducing Iberogast to the United States. This plant-based digestive relief product features a clinically proven blend of six herbs designed to address multiple gastrointestinal symptoms, including indigestion, bloating, heartburn, gas, and abdominal discomfort. The launch aimed to provide American consumers with a dual-action solution that not only relieves occasional stomach upsets but also helps restore digestive function. This strategic introduction leveraged the product's long-standing success in international markets to capture a share of the growing demand for natural digestive health solutions.
In March 2024, Sanofi Consumer Healthcare entered into strategic partnerships with Alliance Healthcare and Phoenix Healthcare Distribution to manage the distribution of its portfolio in the United Kingdom. This collaboration aimed to enhance the logistics and availability of its consumer health products, including key gastrointestinal over-the-counter brands such as Buscopan and Dulcolax. The agreement was designed to streamline the supply chain and ensure that these essential digestive health medications remained readily accessible to pharmacies and consumers across the region. This move reflected the company's commitment to optimizing its operations and strengthening its foothold in the Global Gastrointestinal OTC Drugs Market.

Key Market Players

Viatris Inc.
Sandoz Group AG
Johnson & Johnson Services, Inc.
Sun Pharmaceuticals Industries Limited
Teva Pharmaceuticals Industries Ltd.
Zydus Life science Ltd.
Sanofi SA
Bayer AG
Pfizer Inc.
GlaxoSmithKline Plc.

By Drug Class	By Indication	By End User	By Region
Laxatives Gastrointestinal Cancer Treatments Gastric Acid Reducers Anti-Diarrheal Proton Pump Inhibitors H2 Inhibitors Gastric Acid Neutralizers Bowel Anti-Inflammatory Anti-Emetics	Gastroesophageal Reflux Disease or Heartburn Constipation Diarrhea Motion Sickness Others	Hospitals Pharmacies Retail Pharmacies Online pharmacies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Gastrointestinal OTC Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastrointestinal OTC Drugs Market, By Drug Class:

Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics

Gastrointestinal OTC Drugs Market, By Indication:

Gastroesophageal Reflux Disease or Heartburn
Constipation
Diarrhea
Motion Sickness
Others

Gastrointestinal OTC Drugs Market, By End User:

Hospitals Pharmacies
Retail Pharmacies
Online pharmacies
Others

Gastrointestinal OTC Drugs Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal OTC Drugs Market.

Available Customizations:

Global Gastrointestinal OTC Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Gastrointestinal OTC Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gastrointestinal OTC Drugs Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Drug Class (Laxatives, Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal, Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel Anti-Inflammatory, Anti-Emetics)

5.2.2. By Indication (Gastroesophageal Reflux Disease or Heartburn, Constipation, Diarrhea, Motion Sickness, Others)

5.2.3. By End User (Hospitals Pharmacies, Retail Pharmacies, Online pharmacies, Others)

5.2.4. By Region

5.2.5. By Company (2025)

5.3. Market Map

6. North America Gastrointestinal OTC Drugs Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Drug Class

6.2.2. By Indication

6.2.3. By End User

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Gastrointestinal OTC Drugs Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Drug Class

6.3.1.2.2. By Indication

6.3.1.2.3. By End User

6.3.2. Canada Gastrointestinal OTC Drugs Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Drug Class

6.3.2.2.2. By Indication

6.3.2.2.3. By End User

6.3.3. Mexico Gastrointestinal OTC Drugs Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Drug Class

6.3.3.2.2. By Indication

6.3.3.2.3. By End User

7. Europe Gastrointestinal OTC Drugs Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Drug Class

7.2.2. By Indication

7.2.3. By End User

7.2.4. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Gastrointestinal OTC Drugs Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Drug Class

7.3.1.2.2. By Indication

7.3.1.2.3. By End User

7.3.2. France Gastrointestinal OTC Drugs Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Drug Class

7.3.2.2.2. By Indication

7.3.2.2.3. By End User

7.3.3. United Kingdom Gastrointestinal OTC Drugs Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Drug Class

7.3.3.2.2. By Indication

7.3.3.2.3. By End User

7.3.4. Italy Gastrointestinal OTC Drugs Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Drug Class

7.3.4.2.2. By Indication

7.3.4.2.3. By End User

7.3.5. Spain Gastrointestinal OTC Drugs Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Drug Class

7.3.5.2.2. By Indication

7.3.5.2.3. By End User

8. Asia Pacific Gastrointestinal OTC Drugs Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Drug Class

8.2.2. By Indication

8.2.3. By End User

8.2.4. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Gastrointestinal OTC Drugs Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Drug Class

8.3.1.2.2. By Indication

8.3.1.2.3. By End User

8.3.2. India Gastrointestinal OTC Drugs Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Drug Class

8.3.2.2.2. By Indication

8.3.2.2.3. By End User

8.3.3. Japan Gastrointestinal OTC Drugs Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Drug Class

8.3.3.2.2. By Indication

8.3.3.2.3. By End User

8.3.4. South Korea Gastrointestinal OTC Drugs Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Drug Class

8.3.4.2.2. By Indication

8.3.4.2.3. By End User

8.3.5. Australia Gastrointestinal OTC Drugs Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Drug Class

8.3.5.2.2. By Indication

8.3.5.2.3. By End User

9. Middle East & Africa Gastrointestinal OTC Drugs Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Drug Class

9.2.2. By Indication

9.2.3. By End User

9.2.4. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Gastrointestinal OTC Drugs Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Drug Class

9.3.1.2.2. By Indication

9.3.1.2.3. By End User

9.3.2. UAE Gastrointestinal OTC Drugs Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Drug Class

9.3.2.2.2. By Indication

9.3.2.2.3. By End User

9.3.3. South Africa Gastrointestinal OTC Drugs Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Drug Class

9.3.3.2.2. By Indication

9.3.3.2.3. By End User

10. South America Gastrointestinal OTC Drugs Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Drug Class

10.2.2. By Indication

10.2.3. By End User

10.2.4. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Gastrointestinal OTC Drugs Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Drug Class

10.3.1.2.2. By Indication

10.3.1.2.3. By End User

10.3.2. Colombia Gastrointestinal OTC Drugs Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Drug Class

10.3.2.2.2. By Indication

10.3.2.2.3. By End User

10.3.3. Argentina Gastrointestinal OTC Drugs Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Drug Class

10.3.3.2.2. By Indication

10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Gastrointestinal OTC Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Viatris Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Sandoz Group AG

15.3. Johnson & Johnson Services, Inc.

15.4. Sun Pharmaceuticals Industries Limited

15.5. Teva Pharmaceuticals Industries Ltd.

15.6. Zydus Life science Ltd.

15.7. Sanofi SA

15.8. Bayer AG

15.9. Pfizer Inc.

15.10. GlaxoSmithKline Plc.

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Gastrointestinal OTC Drugs Market in 2025?

Which is the dominating region in the Global Gastrointestinal OTC Drugs Market?

Which is the fastest growing segment in the Global Gastrointestinal OTC Drugs Market?

What is the expected growth rate of the Global Gastrointestinal OTC Drugs Market?